Cargando…
Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
BACKGROUND: In a recent study, autoantibodies neutralizing type I interferons (IFNs) were present in at least 10% of cases of critical COVID-19 pneumonia. These autoantibodies neutralized most type I IFNs but rarely IFN-beta. OBJECTIVES: We aimed to define the prevalence of autoantibodies neutralizi...
Autores principales: | Troya, Jesús, Bastard, Paul, Planas-Serra, Laura, Ryan, Pablo, Ruiz, Montse, de Carranza, María, Torres, Juan, Martínez, Amalia, Abel, Laurent, Casanova, Jean-Laurent, Pujol, Aurora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043439/ https://www.ncbi.nlm.nih.gov/pubmed/33851338 http://dx.doi.org/10.1007/s10875-021-01036-0 |
Ejemplares similares
-
Low Lymphocytes and IFN-Neutralizing Autoantibodies as Biomarkers of COVID-19 Mortality
por: Troya, Jesús, et al.
Publicado: (2022) -
No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
por: Philippot, Quentin, et al.
Publicado: (2023) -
Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022) -
Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β
por: Vinh, Donald C., et al.
Publicado: (2021) -
Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
por: Philippot, Quentin, et al.
Publicado: (2023)